Bausch & Lomb Acquires Rights To Recombinant Plasmin from Talecris Biotherapeutics for Ophthalmic Use

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics by ruth on August 31, 2006

Bausch & Lomb, a manufacturer of eye care products is expanding an agreement with biotechnology firm, Talecris Biotherapeutics, to develop a recombinant plasmin.Bausch & Lomb believes rplasmin have potentials for use in developing novel therapies for ocular conditions, particularly those for in which surgery is the primary treatment option.

Under the new license, Bausch & Lomb will help develop rPlasmin, a recombinant derivative of the human blood component plasmin that helps to dissolve blood clots. Bausch & Lomb will get rights to the compound for eye care applications, whereas Talecris will retain rights for non-eye uses like treating blood clots in veins and arteries.

B&L is enrolling patients in early-stage clinical trials to evaluate Plasmin's therapeutic potential to relieve retinal traction.

[Source/Image: Bausch & Lomb]

Related Entries:

Recombinant Tuberculosis Vaccine - 29 August 2005
Plectasin: Novel Antimicrobial Peptide - 12 October 2005
Cephalon Acquires Rights To Psoriasis Drug Candidate - 12 December 2005
FDA Approves Akorn's Generic Ketotifen Fumarate Ophthalmic S... - 29 July 2007

« EU Anxious About US GMO-C... | Main | Tangled Bank #61 on Epige... »

Permalink: Bausch & Lomb Acquires Rights To Recombinant Plasmin from Talecris Biotherapeutics for Ophthalmic Use

Tags: opthalmology recombinant biotech rights lomb bausch+lomb talecris+biotherapeutics acquires+rights

Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/34938

Addthis

Ask

Blinklist

del.icio.us

Digg

Fark

Facebook

Google

Lycos

Ma.gnolia

Mr Wong

Netscape

Netvousz

Newsvine

StumbleUpon

Slashdot

Tailrank

Technorati

Wink

Yahoo

Vote for Bausch & Lomb Acquires Rights To Recombinant Plasmin from Talecris Biotherapeutics for Ophthalmic Use:

Currently 8.00/10
1
2
3
4
5
6
7
8
9
10

Rating: 8.00 out of 1 vote(s) cast.

Add your response to Bausch & Lomb Acquires Rights To Recombinant Plasmin from Talecris Biotherapeutics for Ophthalmic Use:

Name: *

Email: (will never be shown)*

URL:

(* marked fields are required)

Notify me if more comments appear?

Subscribe to The Biotech Weblog newsletter? (Newsletters are sent out weekly).

Remember me

Security Code: *
(Please help us to sort out spam.)

Please enter your comment here: (Sorry, no HTML is allowed - URLs will be made clickable automatically if you add http:// to your URL.)

We welcome your comments, however all comments are moderated. Offensive or off-topic comments will be deleted and not displayed.

Share It

Use the search to look for other interesting posts

Contributors (Last 90 days)

Gloria Gamat (4)
Ruth Schaffer (10)
Creative Weblogging (4)

This site has 1327 entries and is powered by Creative Weblogging since July 2005.

Our Editors recommend

Disclaimer

Some of the contents of this site are protected Creative Weblogging Inc. 2004-2010.

Check out our Sponsored Blogs!

Business Computer Blog (UK)

Are you interested in writing a blog in our network?

See which positions are currently open.

Testimonials

'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

'I subscribe to your blog and have been enjoying your posts and perspective.'

Other blogs in the same channel in the Creative Weblogging Network: Health & Life Sciences

RSS	See all blog subscribe options
Google	What is RSS?
Yahoo!
Addthis
Bloglines
Newsletter
Twitter	Follow us on Twitter!